| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Journal of Clinical Endocrinology & Metabolism, Vol 67, 46-53, Copyright © 1988 by Endocrine Society
ARTICLES |
A Miyauchi, M Fukase, M Tsutsumi and T Fujita
Department of Medicine, Kobe University School of Medicine, Japan.
Although more than 50 patients with the tumor-induced osteomalacia syndrome, characterized by remission of unexplained osteomalacia after resection of a coexisting tumor, have been reported, the pathogenesis of this syndrome is still not clear. We investigated the cause of biopsy-confirmed osteomalacia which was resistant to treatment with 1 alpha-hydroxyvitamin D3 in a 54-yr-old man. He had severe hypophosphatemia, a high serum alkaline phosphatase level, a low plasma 1,25-dihydroxyvitamin D level, and remarkably increased urinary phosphorus excretion. A tumor, with histological characteristics of a hemangiopericytoma, was found on his left thigh. After surgical removal of this tumor, his plasma 1,25-dihydroxyvitamin D and serum phosphorus levels increased to normal levels, and his bone pain subsided. The tumor was transplanted to athymic nude mice. A nodule formed in each mouse, with histological features identical to those of the original tumor, and the tumor-bearing mice had hypophosphatemia, high serum alkaline phosphatase levels, and increased urinary phosphorus excretion. When extracts of the original tumor were added to primary cultures of renal tubular cells, renal cAMP levels did not change, but 25-hydroxyvitamin D-1 alpha-hydroxylase activity was significantly inhibited. These data indicate tumoral production of some humoral factor(s) inhibiting 25-hydroxyvitamin D-1 alpha-hydroxylase activity and phosphorus reabsorption unrelated to adenylate cyclase-cAMP production in proximal renal tubules.
This article has been cited by other articles:
![]() |
S. M. Jan de Beur Tumor-Induced Osteomalacia JAMA, September 14, 2005; 294(10): 1260 - 1267. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S.N. Rowe THE WRICKKENED PATHWAYS OF FGF23, MEPE AND PHEX Crit. Rev. Oral. Biol. Med., September 1, 2004; 15(5): 264 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Nelson, R. C. Bligh, M. Mirams, A. Gill, A. Au, A. Clarkson, H. Juppner, S. Ruff, P. Stalley, R. A. Scolyer, et al. Fibroblast Growth Factor 23: A New Clinical Marker for Oncogenic Osteomalacia J. Clin. Endocrinol. Metab., September 1, 2003; 88(9): 4088 - 4094. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Saito, K. Kusano, M. Kinosaki, H. Ito, M. Hirata, H. Segawa, K.-i. Miyamoto, and N. Fukushima Human Fibroblast Growth Factor-23 Mutants Suppress Na+-dependent Phosphate Co-transport Activity and 1alpha ,25-Dihydroxyvitamin D3 Production J. Biol. Chem., January 17, 2003; 278(4): 2206 - 2211. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. R. Clunie, P. E. Fox, and T. C. B. Stamp Four cases of acquired hypophosphataemic ('oncogenic') osteomalacia. Problems of diagnosis, treatment and long-term management Rheumatology, December 1, 2000; 39(12): 1415 - 1421. [Full Text] [PDF] |
||||
![]() |
P S N ROWE The molecular background to hypophosphataemic rickets Arch. Dis. Child., September 1, 2000; 83(3): 192 - 194. [Full Text] [PDF] |
||||
![]() |
S. J. Yeung, I. E. McCutcheon, P. Schultz, and R. F. Gagel Use of Long-Term Intravenous Phosphate Infusion in the Palliative Treatment of Tumor-Induced Osteomalacia J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 549 - 555. [Abstract] [Full Text] |
||||
![]() |
T. A. Guise and G. R. Mundy Cancer and Bone Endocr. Rev., February 1, 1998; 19(1): 18 - 54. [Abstract] [Full Text] |
||||
![]() |
Q. Cai, S. F. Hodgson, P. C. Kao, V. A. Lennon, G. G. Klee, A. R. Zinsmiester, and R. Kumar Inhibition of Renal Phosphate Transport by a Tumor Product in a Patient with Oncogenic Osteomalacia N. Engl. J. Med., June 9, 1994; 330(23): 1645 - 1649. [Full Text] |
||||
![]() |
A. Hanukoglu, S.A. Chalew, C.J. Sun, H.D. Dorfman, and R.W. Bright Surgically Curable Hypophosphatemic Rickets: Diagnosis and Management Clinical Pediatrics, July 1, 1989; 28(7): 321 - 325. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |